Artelo Biosciences, Inc.
ARTL Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$2.20
KIRA · Stoqly’s AI analyst, in plain words
- Artelo Biosciences, Inc. lost $12.9M in fiscal 2025.
Market cap
$6.0M
P/E
0.2x
Revenue
—
Net income
−$12.9M
Free cash flow
—
Operating margin
—
Artelo Biosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$12.9M
No. It lost money last year.
How is the share priced?
0.2x
One share costs 0.2 times its yearly profit per share.
What Artelo Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- ARTELO BIOSCIENCES, INC.
- CIK
- 0001621221
Artelo Biosciences, Inc. · ARTL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$7.4M | −$10.1M | −$9.3M | −$9.8M | −$12.9M |
| Diluted EPS | −$0.40 | — | −$3.14 | −$18.30 | −$12.52 |
| Cash | |||||
| Cash from operations | −$6.1M | −$8.0M | −$8.2M | −$8.4M | −$8.5M |
| Share count change | −99.5% | — | — | −81.9% | 91.6% |
| Debt and strength | |||||
| Cash and short-term investments | $24.1M | $16.0M | $10.4M | $2.3M | $0.6M |
| Shareholders' equity | $27.2M | $19.4M | $11.8M | $2.9M | −$1.3M |
| Current ratio | 24.0x | 18.4x | 8.5x | 1.4x | 0.2x |
| Interest coverage | — | −2,057.4x | — | — | −58.8x |
| Returns and quality | |||||
| Return on equity | −47.9% | −43.3% | −59.6% | −134.5% | −1,625.1% |
| Return on tangible equity | −29.6% | −58.1% | −95.6% | −1,201.2% | — |
| Altman Z'' | 27.6 | 17.2 | −0.8 | −46.5 | −108.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Artelo Biosciences, Inc. · ARTL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.20 a share, the company is worth $6.0M: 0.2 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001621221). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.